Medigen Biotechnology Corp. announced the appointment of Mr. Chieh-Liang Lin, Senior Associate Vice President of Cell Therapy Department of the company, as Chief Scientific Officer. Approved by the Board of Directors on March 11, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.5 TWD | +2.20% | -2.47% | -11.83% |
1st Jan change | Capi. | |
---|---|---|
-11.83% | 166M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- 3176 Stock
- News Medigen Biotechnology Corp.
- Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer